3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
Follow MLN2238: new trials by email Literature Review of MLN2238 trials Research Report on MLN2238
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Ixazomib, Ixazomib Citrate, Rituximab - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2019-08-28 | 2025-04-20 |
| Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 2 | Unknown | Emory University | 49 | 2019-07-03 | 2024-06-21 |
| Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma Dexamethasone, Ixazomib, Ixazomib Citrate - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-06-21 | 2019-03-26 | |
| Myeloma-Developing Regimens Using Genomics (MyDRUG) Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Multiple Myeloma Research Consortium | 103 | 2019-04-01 | 2025-02-14 |
| Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Bortezomib, Daratumumab, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-01-17 | 2026-10-06 |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Doxorubicin, Doxorubicin Hydrochloride, Gemcitabine - Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 30 | 2018-08-17 | 2026-08-11 |
| Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis Daratumumab, Dexamethasone, Ixazomib - Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis | Phase 1 | Completed | M.D. Anderson Cancer Center | 21 | 2018-02-07 | 2026-07-09 |
Multiple Myeloma (4) · Carcinoma, Renal Cell (1) · Immunoglobulin Light-chain Amyloidosis (1) · Lymphoma, Mantle-Cell (1)
M.D. Anderson Cancer Center (4) · Emory University (1) · Multiple Myeloma Research Consortium (1) · National Cancer Institute (NCI) (1)
United States (6)
Ajay Nooka, MD, MPH (1) · Hearn J Cho, M.D., Ph.D. (1) · Hun J Lee (1) · Oren C Pasvolsky, MD (1) · Oren Pasvolsky (1) · Pavlos Msaouel (1) · Taiga Nishihori (1)
P30CA138292 (1), UM1CA186644 (1)